539
Participants
Start Date
April 30, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Novartis Investigational H5N1 vaccine
2 doses of 0.5 ml, 3 weeks apart
Novartis Investigational H5N1 vaccine
2 doses of 0.5 ml, 3 weeks apart
Novartis Seasonal Influenza Vaccine
2 doses of 0.5 ml, 3 weeks apart
Novartis Seasonal Influenza Vaccine
2 doses of 0.5 ml, 3 weeks apart
102, Novartis Investigational Site, Darlinghurst
103, Novartis Investigational Site, Darlinghurst
101, Novartis Investigational Site, Merewether
304, Novartis Investigational Site, Rostock
003, Novartis Investigational Site, Monza
001, Novartis Investigational Site, Milan
002, Novartis Investigational Site, Milan
006, Novartis Investigational Site, San Daniele del Friuli
007, Novartis Investigational Site, Aviano
302, Novartis Investigational Site, Hamburg
301, Novartis Investigational Site, Magdeburg
004, Novartis Investigational Site, Parma
005, Novartis Investigational Site, Chieti
008, Novartis Investigational Site, Chieti
082, Novartis Investigational Site, Fossacesia
081, Novartis Investigational Site, Lanciano
303, Novartis Investiagtional Site, Würzburg
Collaborators (1)
Novartis Vaccines
INDUSTRY
Seqirus
INDUSTRY